Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Promethazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 3/20 | 0.97 |
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 3/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | GFER | P55789 | 3/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 2/20 | 1.00 |
| ▸ | GMNN | O75496 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.97 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.97 |
| ▸ | HTR1A | P08908 | 6/20 | 0.97 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.97 |
| ▸ | ADRA1A | P35348 | 6/20 | 0.97 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.97 |
| ▸ | DRD3 | P35462 | 6/20 | 0.97 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.97 |
| ▸ | ADRA2A | P08913 | 5/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Promethazine SCHEMBL5501515 | 1.00 | LMNA (1.00) | LMNAMAPTSMN1; SMN2MAPK1HIF1A | |
| Promethazine SCHEMBL2962420 | 1.00 | LMNA (1.00) | LMNAMAPTSMN1; SMN2MAPK1HIF1A | |
| Promethazine SCHEMBL29390401 | 1.00 | LMNA (1.00) | LMNAMAPTSMN1; SMN2MAPK1HIF1A | |
| Promethazine SCHEMBL27559626 | 1.00 | LMNA (1.00) | LMNAMAPTSMN1; SMN2MAPK1HIF1A | |
| Promethazine SCHEMBL41904 | 1.00 | LMNA (1.00) | LMNAMAPTSMN1; SMN2MAPK1HIF1A | |
| Promethazine SCHEMBL3991025 | 0.98 | LMNA (0.97) | LMNAMAPTSMN1; SMN2MAPK1HIF1A | |
| (S)-Promethazine SCHEMBL2900853 | 0.98 | CYP2D6 (1.00) | LMNAMAPTSMN1; SMN2MAPK1HIF1A | |
| Promethazine SCHEMBL29372077 | 0.98 | CYP2D6 (1.00) | LMNAMAPTSMN1; SMN2MAPK1HIF1A | |
| Promethazine SCHEMBL26777 | 0.98 | CYP2D6 (1.00) | LMNAMAPTSMN1; SMN2MAPK1HIF1A | |
| Promethazine SCHEMBL4700 | 0.98 | CYP2D6 (1.00) | LMNAMAPTSMN1; SMN2MAPK1HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070060636-A1 | High enantiomeric purity dexanabinol for pharmaceutical compositions | PHARMOS CORPORATION | 2007-03-15 | — | — | US | disclosed |
| EP-1567513-A2 | HIGH ENANTIOMERIC PURITY DEXANABINOL FOR PHARMACEUTICAL COPOSITIONS | PHARMOS CORPORATION (US) | 2005-08-31 | — | — | EP | disclosed |
| WO-2004050011-A2 | HIGH ENANTIOMERIC PURITY DEXANABINOL FOR PHARMACEUTICAL COPOSITIONS | PHARMOS CORPORATION (US) | 2004-06-17 | — | — | WO | disclosed |
| US-20040110827-A1 | High enantiomeric purity dexanabinol for pharmaceutical compositions | PHARMOS CORPORATION | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060636-A1 | High enantiomeric purity dexanabinol for pharmaceutical compositions | CNR2, CNR1, PDE8B | HRH1 643/4885LMNA 2669/4885MAPT 1160/4885 |
| US-20040110827-A1 | High enantiomeric purity dexanabinol for pharmaceutical compositions | CNR2, CNR1, PDE8B | HRH1 643/4885LMNA 2669/4885MAPT 1160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.